




PHARMACEUTICAL 2018

JOHNSON & JOHNSON
Rank 176 of 342





RealRate

PHARMACEUTICAL 2018

JOHNSON & JOHNSON Rank 176 of 342



The relative strengths and weaknesses of JOHNSON & JOHNSON are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of JOHNSON & JOHNSON compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 90% points. The greatest weakness of JOHNSON & JOHNSON is the variable Assets, Current, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 37% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	43,088,000
Cost of Goods Sold	0
Intangible Assets	85,134,000
Liabilities, Current	30,537,000
Liabilities, Non-Current	39,692,000
Other Assets	12,076,000
Other Compr. Net Income	1,702,000
Other Expenses	43,378,000
Other Liabilities	26,914,000
Other Net Income	202,000
Other Revenues	76,450,000
Property and Equipment	17,005,000
Research and Development	10,554,000
Selling, General and Administrative Expense	21,420,000

Output Variable	Value in 1000 USD
Assets	157,303,000
Liabilities	97,143,000
Expenses	75,352,000
Revenues	76,450,000
Stockholders Equity	60,160,000
Net Income	1,300,000
Comprehensive Net Income	2,151,000
Economic Capital Ratio	83%